Table 1 Demographic and clinical data of the subjects enrolled for the study.
Demographic data | Healthy subjects | AD patients | P value |
|---|---|---|---|
Number | 26 | 42 | – |
Male (% of total) | 12 (46.2) | 14 (33.3) | 0.2904* |
Female (% of total) | 14 (53.8) | 28 (66.7) | |
Age, range (years) | 64–86 | 64–87 | – |
Male, range (years) | 64–86 | 64–87 | – |
Female, range (years) | 66–84 | 68–86 | – |
Age, mean ± SD (SEM) | 76.7 ± 5.9 (1.16) | 79.1 ± 5.4 (0.83) | 0.0834 |
Male, age, mean ± SD (SEM) | 76.8 ± 7.2 (2.08) | 78.5 ± 5.4 (1.44) | 0.4687 |
Female, age, mean ± SD (SEM) | 76.6 ± 4.8 (1.28) | 79.4 ± 5.4 (1.03) | 0.0711 |
CDR, mean ± SD (SEM) | NA | 1.41 ± 0.50 (0.077) | – |
Male, CDR, mean ± SD (SEM) | NA | 1.43 ± 0.51 (0.14) | – |
Female, CDR, mean ± SD (SEM) | NA | 1.39 ± 0.50 (0.094) | – |
CDR, number (in parentheses) and age, mean ± SD (SEM) | |||
CDR 1 (25) | NA | 77.9 ± 5.7 (1.15) | 0.1012** |
CDR 2 (17) | NA | 80.9 ± 4.4 (1.06) | |
No. of subjects using anti-dementia drugs (% of total)a | NA | 38 (90.5) | |
Memantine, number (% of total) | NA | 19 (42.9) | – |
Memantine, mg/die, mean ± SD (SEM) | NA | 18.4 ± 3.8 (0.86) | – |
Donepezil, number (% of total) | NA | 14 (33.3) | – |
Donepezil, mg/die, mean ± SD (SEM) | NA | 7.5 ± 2.6 (0.69) | – |
Rivastigmine, number (% of total) | NA | 7 (16.7) | – |
Rivastigmine, mg/die, mean ± SD (SEM) | NA | 6.6 ± 2.1 (0.79) | – |
